Vertex Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Vertex Pharmaceuticals filed its Q1 2024 10-Q, detailing financial performance and segment revenues.</b>

AI Summary

VERTEX PHARMACEUTICALS INC / MA (VRTX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Vertex Pharmaceuticals reported financial results for the quarter ended March 31, 2024. The filing details financial data including common stock, additional paid-in capital, accumulated other comprehensive income, and retained earnings as of various dates. Revenue segments include TRIKAFTA/Kaftrio and Other Cystic Fibrosis Products. Geographic revenue breakdown includes US, Europe, and Other Non-U.S. regions. Key dates mentioned relate to financial reporting periods and specific agreements like the CRISPR Therapeutics AG collaboration.

Why It Matters

For investors and stakeholders tracking VERTEX PHARMACEUTICALS INC / MA, this filing contains several important signals. This 10-Q provides an update on Vertex's financial health and operational performance for the first quarter of 2024, crucial for investors assessing the company's trajectory. The filing includes specific financial figures and segment data, allowing for a detailed analysis of revenue streams and capital structure, particularly concerning their cystic fibrosis products.

Risk Assessment

Risk Level: low — VERTEX PHARMACEUTICALS INC / MA shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial disclosures without immediate red flags, indicating a low level of risk from this specific document.

Analyst Insight

Review the detailed revenue breakdown by segment and geography to understand growth drivers and potential market penetration for key products like TRIKAFTA/Kaftrio.

Revenue Breakdown

Key Numbers

• 2024-03-31 — Report Period End Date (Conformed Period of Report)
• 2024-05-07 — Filing Date (Filed as of date)

Key Players & Entities

• VERTEX PHARMACEUTICALS INC / MA (company) — Filer name
• CRISPR Therapeutics AG (company) — Mentioned in relation to a collaboration agreement.

FAQ

Industry Context

Vertex Pharmaceuticals operates in the pharmaceutical industry, focusing on developing transformative medicines for serious diseases.

Regulatory Implications

This filing is a standard 10-Q, adhering to SEC regulations for quarterly financial reporting by public companies.

What Investors Should Do

1. Analyze the detailed financial statements for revenue trends and profitability.
2. Examine the notes to the financial statements for any significant accounting policies or disclosures.
3. Compare Q1 2024 performance against Q1 2023 to identify year-over-year changes.

Key Dates

• 2024-03-31: Quarterly Period End — Financial results for Q1 2024 are reported.
• 2024-05-07: Filing Date — The 10-Q report was officially filed.

Year-Over-Year Comparison

This is the Q1 2024 10-Q filing, providing updated financial information compared to previous filings.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G

Filing Documents

• vrtx-20240331.htm (10-Q) — 1123KB
• a2024q110-qexhibit311.htm (EX-31.1) — 10KB
• a2024q110-qexhibit312.htm (EX-31.2) — 10KB
• a2024q110-qexhibit321.htm (EX-32.1) — 6KB
• vrtx-20240331_g1.jpg (GRAPHIC) — 62KB
• 0000875320-24-000139.txt (&nbsp;) — 6838KB
• vrtx-20240331.xsd (EX-101.SCH) — 42KB
• vrtx-20240331_cal.xml (EX-101.CAL) — 81KB
• vrtx-20240331_def.xml (EX-101.DEF) — 221KB
• vrtx-20240331_lab.xml (EX-101.LAB) — 564KB
• vrtx-20240331_pre.xml (EX-101.PRE) — 414KB
• vrtx-20240331_htm.xml (XML) — 1082KB

Financial Information

Part I. Financial Information Item 1.

Financial Statements

Financial Statements 2 Condensed Consolidated Financial Statements (unaudited) 2 Condensed Consolidated Statements of Income - Three Months Ended March 31, 2024 and 2023 2 Condensed Consolidated Statements of Comprehensive Income - Three Months Ended March 31, 2024 and 2023 3 Condensed Consolidated Balance Sheets - March 31, 2024 and December 31, 2023 4 Condensed Consolidated Statements of Shareholders' Equity - Three Months Ended March 31, 2024 and 2023 5 Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 32

Other Information

Part II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 5. Other Information 34 Item 6. Exhibits 35

Signatures

Signatures 36 "Vertex," "we," "us," and "our" as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries. "Vertex ," "KALYDECO ," "ORKAMBI ," "SYMDEKO ," "SYMKEVI ," "TRIKAFTA ," "KAFTRIO ," and CASGEVY" are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners. We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our development programs, we refer to our compounds and therapies by their scientific (or generic) name or VX developmental designation. Table of Contents

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements VERTEX PHARMACEUTICALS INCORPORATED Condensed Consolidated Statements of Income (in millions, except per share amounts)(unaudited) Three Months Ended March 31, 2024 2023 Product revenues, net $ 2,690.6 $ 2,374.8 Costs and expenses: Cost of sales 342.6 266.9 Research and development expenses 789.1 742.6 Acquired in-process research and development expenses 76.8 347.1 Selling, general and administrative expenses 342.7 241.1 Change in fair value of contingent consideration ( 0.1 ) ( 1.9 ) Total costs and expenses 1,551.1 1,595.8 Income from operations 1,139.5 779.0 Interest income 181.2 122.6 Interest expense ( 10.4 ) ( 11.4 ) Other (expense) income, net ( 31.2 ) 1.3 Income before provision for income taxes 1,279.1 891.5 Provision for income taxes 179.5 191.7 Net income $ 1,099.6 $ 699.8 Net income per common share: Basic $ 4.26 $ 2.72 Diluted $ 4.21 $ 2.69 Shares used in per share calculations: Basic 258.2 257.4 Diluted 261.1 260.3 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Table of Contents VERTEX PHARMACEUTICALS INCORPORATED Condensed Consolidated Statements of Comprehensive Income (in millions)(unaudited) Three Months Ended March 31, 2024 2023 Net income $ 1,099.6 $ 699.8 Other comprehensive income (loss): Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $ 5.4 and $( 0.8 ), respectively ( 19.7 ) 2.9 Unrealized gains (losses) on foreign currency forward contracts, net of tax of $( 12.3 ) and $ 7.4 , respectively 44.5 ( 26.8 ) Foreign currency translation adjustment 6.8 10.0 Total other comprehensive income (loss) 31.6 ( 13.9 ) Comprehensive income $ 1,131.2 $ 685.9 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents VERTEX PHARMACEUTICALS INCORPORATED Condensed Consolidated Balance Sheets (in millions, except share da

View Full Filing

View this 10-Q filing on SEC EDGAR